secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146179
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO
---------------------------------------------------------

- Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.
- Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.
- Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.
- Topline results from Part B of SIGNAL-AA expected in first half of 2026.
- Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/0001193125-25-146179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/d917821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer